Latest news with #AnthemBiosciencesLimited
News18
21-07-2025
- Business
- News18
Anthem Biosciences IPO Lists Today: 67× Subscription, Strong GMP; Big Listing On Cards?
Select the IPO: From the dropdown menu, choose 'Anthem Biosciences Limited'. Note that the IPO name will only appear once the allotment is finalised. Enter Details: Input the details corresponding to the selected mode (e.g., your PAN, application number, or Demat account details). Complete CAPTCHA: Fill in the CAPTCHA for security verification and click 'Submit' to view your allotment status. The status will show whether shares were allotted and, if so, how many. Option 2: Check Allotment Status on BSE Website You can also check the allotment status on the BSE website. Here's how: Visit the BSE IPO Page: Go to Select Issue Type: Choose 'Equity" as the issue type. Select IPO: From the dropdown menu, select 'Anthem Biosciences Limited'. Enter Details: Provide your Application Number or PAN. Complete CAPTCHA: Tick the 'I'm not a robot" CAPTCHA and click 'Search" to view your allotment status. Anthem Biosciences IPO: More Info The IPO is entirely an offer-for-sale (OFS). So, the company will not receive any funds from the issue and the proceeds will go to the selling shareholders. Anthem Biosciences raised Rs 1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription. Some of the investors that participated in the anchor book are — Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF. Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
India Today
17-07-2025
- Business
- India Today
Anthem Biosciences IPO: Allotment status live. GMP, listing details here
The allotment of shares for the initial public offering (IPO) of Anthem Biosciences Limited is set to be finalised on Thursday, July 17, Biosciences IPO, which opened for subscription on July 14 and closed on July 16, received an overwhelming response from investors across public issue, worth Rs 3,395 crore, was subscribed 67.42 times in total. This includes 5.98 times in the retail category, 192.80 times in the qualified institutional buyers (QIB) category, and 44.70 times in the non-institutional investors (NII) category by the end of Day strong demand reflects high investor interest in the company, even though the Anthem Biosciences IPO was entirely an offer for sale (OFS) of 5.96 crore equity shares by existing Biosciences itself will not receive any direct funds from the offer. The price band for the issue was fixed at Rs 570 per TO CHECK ALLOTMENT STATUS ONLINEInvestors who applied for the Anthem Biosciences IPO can check their allotment status online through two platforms: the BSE website and the website of the IPO registrar, KFin BSE Website:Visit the official BSE allotment status "Issue Type", select "Equity".From the "Issue Name" dropdown, choose "Anthem Biosciences Limited".Enter your application your PAN the captcha and click "Search".Via KFin Technologies Website:Visit the KFin Technologies IPO status "Anthem Biosciences Limited" from the your preferred method to search: Application Number, Demat Account Number or your application type: ASBA or in the required details and complete the "Submit" to view your allotment MARKET PREMIUM (GMP) TRENDThe grey market premium (GMP) for Anthem Biosciences IPO has been steadily climbing but saw a slight dip a day before the of July 17 at 7:29 AM, the latest GMP stands at Rs 144. Given the upper price band of Rs 570, the estimated listing price comes to around Rs 714. This implies a potential listing gain of about 25.26% per share based on the current shares of Anthem Biosciences are expected to list on both the BSE and NSE on Monday, July 21, 2025. Given the strong oversubscription and steady grey market activity, investors are closely watching the listing performance.- Ends advertisement
Mint
14-07-2025
- Business
- Mint
Anthem Biosciences IPO day 1 Live: GMP, subscription status, review, other details. Buy or not?
Anthem Biosciences IPO: The initial public offering (IPO) of Anthem Biosciences Limited has hit the Indian primary market today. The public issue will remain open until 16 July 2025. This means the book build issue will remain open from Monday to Wednesday. The company promoters have declared the Anthem Biosciences IPO price band at ₹ 540 to ₹ 570 per equity share. The company aims to raise ₹ 3,395 crore from this initial offer, which is entirely offer-for-sale (OFS). Anthem Biosciences IPO is proposed for listing on the BSE and the NSE. The company's shares are available in the grey market before the Anthem Biosciences IPO subscription opening. According to market observers, shares of the company are available at a premium of ₹ 101 in the grey market today. 1] Anthem Biosciences IPO GMP: According to market observers, shares of the company are available at a premium of ₹ 101 in the grey market today. 2] Anthem Biosciences IPO subscription date: The public issue has opened today and will remain open until 16 July 2025. 3] Anthem Biosciences IPO price: The company has declared a price band of ₹ 540 to ₹ 570 per equity share. 4] Anthem Biosciences IPO size: The company aims to raise ₹ 3,395 crore from this initial public offering (ipo), which is entirely offer-for-sale (OFS). Photo: Courtesy mintgenie 5] Anthem Biosciences IPO lot size: Bidders can apply in lots, and one lot will comprise 26 company shares. 6] Anthem Biosciences IPO allotment date: The most likely date for share allotment is 17 July 2025. 7] Anthem Biosciences IPO registrar: KFin Technologies Ltd has been appointed registrar of the public issue. 8] Anthem Biosciences IPO lead managers: JM Financial, Citigroup Global Markets, JP Morgan India, and Nomura Financial Advisors have been appointed lead managers of the public offer. 9] Anthem Biosciences IPO listing date: The most likely date for share debut is 21 July 2025. 10] Anthem Biosciences IPO review: Advising invstors to apply for the book-build issue, Arun Kejriwal, Founder of Kejriwal Research and Investment Services, said, "The company is a CRDMO – contract research development and manufacturing organization with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical entity and New Biological Entity Capabilities. The company reported revenues of ₹ 1,844.55 crores and a PAT of ₹ 451 crores for the year ended March 25. The net margins are a healthy 23.4%. The EPS is ₹ 8.04. The PE multiple on a fully diluted basis is at 67.16-70.90," adding, "The key takeaway from this offer for sale is that the promoter founder of the company would continue to hold over 52% of the company and is not selling a single share in the entirely an offer for sale issue. This is a big comforting factor for investors nowadays, who are very wary of the entire offer for sale issues." Anand Rathi has also assigned a 'subscribe' tag to the public issue, saying, "The company has shown a profitable track record against its peers and intends to maintain it by leveraging its integrated manufacturing and technological capabilities by focusing on building complex speciality ingredients, peptides, probiotics, etc. On valuation parse, based on the annualised FY25, it is seeking PE of 70.6 times, and the post-issue market cap comes at ₹ 3,18,673 Mn. With this, the issue is fairly priced. We believe the company has the potential to continue to grow its revenue and profitability ratios compared to its peers. Hence, we give a "SUBSCRIBE" rating for the issue." Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Indian Express
13-07-2025
- Business
- Indian Express
Anthem Biosciences IPO subscription opens on July 14. Check price band, allotment date and more
Anthem Biosciences IPO: The three-day subscription for the initial public offering (IPO) of Anthem Biosciences Limited will open on July 14, Monday. The Anthem Biosciences IPO subscription will close on July 16 (Wednesday). As per the circular, the company has allocated 1.78 crore equity shares to 60 funds at Rs 570 apiece, which is the upper end of the price band. This aggregates the transaction size to Rs 1,016 crore, reports PTI. Anthem Biosciences has raised Rs 1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription. Some of the investors that participated in the anchor book are — Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF, according to BSE. Anthem Biosciences IPO has fixed the price band at Rs 540 to Rs 570 per equity share. KFin Technologies Limited is the registrar of Anthem Biosciences IPO. The face value and tick size of Anthem Biosciences IPO is Rs 2 and Re 1, respectively. According to the details available, the Anthem Biosciences IPO will be July 17. Anthem Biosciences Limited's shares are proposed to be listed on NSE, and BSE. The listing will likely take place on July 21. JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers for the Anthem Biosciences IPO. HDFC Bank Limited and ICICI Bank Limited are the sponsor banks for the Anthem Biosciences IPO. Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. (With inputs from PTI)
